The FDA Quality Management System Regulation (QMSR)

The FDA Quality Management System Regulation (QMSR) represents a major shift in how medical device manufacturers approach compliance in the United States. By aligning closely with ISO 13485, the regulation simplifies global quality management while retaining critical FDA-specific requirements.

This guide explains what QMSR is, how it differs from the legacy QSR, and what manufacturers must do to achieve compliance.

The FDA Quality Management System Regulation (QMSR) is the updated regulatory framework replacing the legacy Quality System Regulation (QSR) under 21 CFR Part 820.

It fundamentally restructures FDA requirements by:

• Embedding ISO 13485:2016 as the core quality management standard
• Retaining additional FDA-specific requirements layered on top
• Creating a unified, globally aligned quality system framework

This shift moves manufacturers from a US-centric model to a globally harmonized quality management approach.

Key objectives of the QMSR include:

• Global harmonization with international standards
• Reduction of duplication between FDA QSR and ISO 13485 systems
• Improved quality management practices through risk-based thinking

For companies operating globally, this enables the transition toward a single, integrated quality management system.

The QMSR final rule was published in February 2024 and introduces a key concept known as incorporation by reference.

This means:

• ISO 13485:2016 is fully incorporated into FDA regulations
• ISO 9000:2015 definitions are also included
• The standards are legally enforceable within the FDA framework

Importantly, ISO 13485 does not replace FDA requirements. Instead, it forms the foundation, with additional FDA obligations remaining mandatory. 

The FDA Quality Management System Regulation (QMSR) became effective on February 2, 2026. There is no additional grace period for compliance.

Following a two-year transition period, manufacturers placing products on the US market must now be fully compliant. 

QSR was structured around prescriptive requirements, whereas QMSR adopts a process-based model aligned with ISO 13485. The shift from QSR to QMSR introduces several critical changes:

• Structural transformation: ISO 13485 is now the foundation,
• Risk-based approach: Strong emphasis on risk management across the product lifecycle
• Integrated systems: Enables consolidation of separate quality frameworks
• Global alignment: Adoption of global state-of-the-art ISO 13485 standard

QMSR is built directly on ISO 13485:2016, making it the central framework for compliance.

This alignment provides:

• A single global QMS structure
• Reduced complexity for multinational manufacturers
• Improved consistency across regulatory regions

Organizations already certified to ISO 13485 are better positioned but alignment alone is not sufficient for FDA compliance. 

Short answer: No.

While ISO 13485 is now embedded in QMSR, it does not cover all FDA regulatory requirements.

Manufacturers must also comply with:

• Additional FDA regulations under 21 CFR
• Specific documentation and reporting requirements
• Detailed expectations for inspection readiness

ISO 13485 provides the framework, but FDA-specific requirements must still be addressed.

Our ISO 13485 training courses are a practical way for you to build confidence in QMSR requirements, especially if you need to understand how ISO 13485 fits within the updated FDA framework.  

QMSR retains several obligations that go beyond ISO 13485, including:

• Medical Device Reporting (MDR)
• Unique Device Identification (UDI)
• Device tracking requirements
• Corrections and removals (recalls)
• Labelling and packaging controls
• Complaint handling and record requirements

These elements are mandatory and subject to FDA inspection.

To achieve compliance with QMSR, organizations typically need to:

• Train personnel on updated regulatory requirements
• Conduct a QMSR gap analysis
• Update internal audit programmes
• Align documentation with the new framework
• Integrate risk-based thinking across processes

Failure to address these areas may result in inspection findings.

A QMSR gap analysis is a critical first step in the transition.

This involves:

• Comparing existing QSR or ISO-based systems against QMSR requirements
• Identifying missing FDA-specific elements
• Evaluating process alignment with ISO 13485

A structured gap assessment helps prioritize actions and supports audit readiness. 

While FDA inspection authority remains unchanged, the approach has evolved.

Key changes include:

• Risk-based inspection methods
• Broader review of QMS performance
• Inclusion of ISO-aligned elements such as:
  • Management review
  • Internal audits
  • Process interactions

Inspectors may now evaluate the entire quality management system, not just isolated elements. 

To prepare effectively, organizations should:

• Transition to an ISO 13485-based QMS structure
• Embed risk-based thinking across the product lifecycle
• Ensure traceability between processes and regulatory requirements
• Update audit programmes to reflect the new inspection approach
• Review documentation to remove outdated QSR references

Organizations often seek external support to ensure a structured and efficient transition.

Explore our ISO 13485 auditing and certification service and detailed QMSR guidance.

The transition from QSR to QMSR marks a significant evolution in medical device regulation. By embedding ISO 13485 and reinforcing risk-based thinking, the FDA has created a more globally aligned and integrated compliance framework.

However, success depends on understanding that ISO alignment is only part of the journey. Manufacturers must also address FDA-specific requirements and prepare for a broader, risk-focused inspection approach. 

With QMSR now in effect, it is important to understand how the new requirements align with ISO 13485 and where additional FDA-specific obligations still apply. Building internal knowledge through training, using our ISO 13485 certification service for your transition, or exploring detailed QMSR guidance can help your team identify gaps, strengthen compliance, and prepare with more confidence. 

With QMSR now in effect, training can help your team understand how ISO 13485 aligns with the new regulation and where FDA-specific requirements still need attention.

Explore our training courses:

• ISO 13485:2016 Training with FDA QMSR (USA/Canada) — 2026 Update
• ISO 13485 Internal Auditor Training with FDA QMSR Update (2026)
• ISO 13485:2016 Lead Auditor Training — With FDA QMSR 2026 & MDSAP Regulatory Update
• ISO 13485:2016 Quality Management Systems Training for Medical Device Manufacturers | Updated with FDA QMSR & MDSAP Requirements